Published in Cancer Weekly, October 9th, 1995
"We are particularly enthusiastic about this trial because our Phase I human study demonstrated that we can safely deliver high levels of the drug that are maintained in the bloodstream for extended periods," said Dr. Elihu Estey, Professor of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.